Mereo BioPharma Group PLC ADR Working Capital to Net Assets Ratio
Mereo BioPharma Group PLC ADR working capital to net assets ratio. Mereo BioPharma Group PLC ADR (MREO) has a Working Capital to Net Assets ratio of 96.8% as of June 2026. Working capital of $27.72 Million (current assets of $33.40 Million minus current liabilities of $5.68 Million) is measured against net assets of $28.65 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check MREO tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Mereo BioPharma Group PLC ADR (2015–2025)
Working capital to net assets ratio of Mereo BioPharma Group PLC ADR from 2015 to 2025. This chart shows how Mereo BioPharma Group PLC ADR's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2015 to 2025. As of June 2026, the ratio stands at 96.8%, reflecting working capital of $27.72 Million against net assets of $28.65 Million USD. See defensive interval ratio of Mereo BioPharma Group PLC ADR to measure how many days the company can operate on defensive assets alone.
Mereo BioPharma Group PLC ADR Working Capital to Net Assets Ratio by Year (2015–2025)
Mereo BioPharma Group PLC ADR working capital to net assets ratio by year from 2015 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Mereo BioPharma Group PLC ADR from 2015 to 2025, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Mereo BioPharma Group PLC ADR total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 99.5% | $40.72 Million | $40.92 Million | $45.02 Million | $4.30 Million | ▼ -0.4 pp |
| 2024 | 99.9% | $60.91 Million | $60.97 Million | $74.76 Million | $13.85 Million | ▼ -7.5 pp |
| 2023 | 107.4% | $54.27 Million | $50.54 Million | $63.76 Million | $9.49 Million | ▲ +8.5 pp |
| 2022 | 98.9% | $50.82 Million | $51.40 Million | $75.20 Million | $24.38 Million | ▲ +0.3 pp |
| 2021 | 98.6% | $117.36 Million | $119.01 Million | $134.32 Million | $16.96 Million | ▲ +240.0 pp |
| 2020 | -141.3% | $28.94 Million | $-20.47 Million | $40.65 Million | $11.71 Million | ▼ -142.7 pp |
| 2019 | 1.4% | $737.86K | $53.33 Million | $40.32 Million | $39.58 Million | ▼ -54.5 pp |
| 2018 | 55.9% | $18.32 Million | $32.77 Million | $34.50 Million | $16.18 Million | ▼ -29.8 pp |
| 2017 | 85.7% | $53.56 Million | $62.48 Million | $63.18 Million | $9.62 Million | ▲ +13.1 pp |
| 2016 | 72.6% | $57.57 Million | $79.26 Million | $60.78 Million | $3.21 Million | ▼ -4.6 pp |
| 2015 | 77.3% | $78.46 Million | $101.54 Million | $81.28 Million | $2.82 Million | — |